DDInter1323 DDInter1082
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Octreotide {u} (Compound) resembles {v} (Compound) Polymyxin B
Octreotide {u} (Compound) resembles {v} (Compound) Bacitracin
Octreotide {u} (Compound) treats {v} (Disease) thymus cancer
Octreotide {u} (Compound) binds {v} (Gene) SSTR2
Octreotide {u} (Compound) palliates {v} (Disease) type 1 diabetes mellitus
Octreotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Octreotide {u} (Compound) causes {v} (Side Effect) Arthropathy
Octreotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Octreotide (Compound) resembles Polymyxin B (Compound)
Octreotide (Compound) resembles Bacitracin (Compound)
Octreotide (Compound) treats thymus cancer (Disease)
Octreotide (Compound) binds SSTR2 (Gene)
Octreotide (Compound) palliates type 1 diabetes mellitus (Disease)
Octreotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Octreotide (Compound) causes Arthropathy (Side Effect)
Octreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human